A recent publication by the Worldwide Antimalarial Resistance Network (WWARN) artesunate-amodiaquine (As-Aq) Study Group in BMC Medicine has demonstrated the real-life health impact of using weight-for-age growth distribution data to inform antimalarial dose development and regimen optimization.

Apart from artemether-lumefantrine (LA), As-Aq is the most widely used antimalarial drug in Africa. It is the second-line drug to treat uncomplicated malaria in Malawi and many other East and Southern African countries, and the first line treatment in many West African countries.